For example, a multicenter study found that CDK 4–6 inhibitors, were effective and safe options for men with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer, similar to their effectiveness in female breast cancer (6). Here, ERBB2 is linked to breast carcinoma.